Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 38 for your search:
Drug:
bleomycin sulfate
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 75
Sponsor:
Other
Protocol IDs:
CGC05MK1002
, NCT00188149
2.
Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
EORTC-20012
, GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595
3.
Phase III Study of Surgery Followed By Compressed Cisplatin, Etoposide, and Bleomycin in Children With Newly Diagnosed Low- or Intermediate-Risk Extracranial Germ Cell Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 21 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-AGCT0132
, NCT00053352, AGCT0132
4.
Phase III Randomized Study of Bleomycin, Etoposide, and Cisplatin With or Without Dose-Dense Sequential Combination Chemotherapy in Patients With Poor Prognosis Stage II or III Non-Seminomatous Germ Cell Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 16
Sponsor:
Other
Protocol IDs:
FRE-FNCLCC-GETUG-13/0206
, EU-20502, NCT00104676
5.
Phase III Study of Observation and/or Chemotherapy Comprising Etoposide, Carboplatin, and Bleomycin With or Without Vinblastine, Ifosfamide, and Cisplatin After Surgical Resection or Biopsy in Pediatric Patients With Extracranial Malignant Germ Cell Tumors
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
CCLG-GC-2005-04
, EUDRACT-2004-002503-33, EU-20584, NCT00274950
6.
Phase III Randomized Study of Short- Versus Long-Infusion Schedule of Bleomycin in Patients Who are Undergoing Combination Chemotherapy Comprising Bleomycin, Etoposide, and Cisplatin for Good-Prognosis, Metastatic Germ Cell Cancer of the Testes
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 50
Sponsor:
Other
Protocol IDs:
BARTS-TE3
, EU-20608, ISRCTN08648791, NCT00324298
7.
Phase III Randomized Study of Early Fludeoxglucose F 18 Positron Emission Tomography Scan-Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Previously Untreated Supradiaphragmatic Stage I or II Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
15 to 70
Sponsor:
Other
Protocol IDs:
EORTC-20051
, GELA-H10, EUDRACT-2005-002765-37, NCT00433433
8.
Phase III Randomized Study of Combination Chemotherapy in Pediatric Patients With Hodgkin's Lymphoma
Phase:
Phase III
Type:
Diagnostic, Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
EURONET-PHL-C1
, EU-20703, EUDRACT-2006-000995-33, NCT00433459, CCLG-HD-2007-10
9.
HD18 for Advanced Stages in Hodgkins Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
HD18
, NCT00515554
10.
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
15 and over
Sponsor:
Other
Protocol IDs:
QL05-37
, NCT00572572
11.
Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CRUK-2007-006064-30
, 2007-006064-30, CRUK-07/146, NCT00678327
12.
HD16 for Early Stage Hodgkin Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
HD16
, NCT00736320
13.
High-Dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
IIL-HD0801
, EudracT Number 2008-002684-14, NCT00784537
14.
Study Evaluating the Effect of Rituximab in Lymphocytic Predominant Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
16 to 65
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ASI-HDIII 0109
, NCT00816959
15.
Phase III Study of Three Different Therapeutic Strategies in Patients With Previously Untreated Hodgkin Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
GOELAMS-LH2007
, GOELAMS LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
16.
Phase III Randomized Study of Fludeoxyglucose F 18 Positron Emission Tomography Imaging in Patients Undergoing Chemotherapy Comprising Doxorubicin Hydrochloride, Bleomycin Sulfate, Vinblastine, and Dacarbazine For Stage IA or IIA Hodgkin Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 75
Sponsor:
Other
Protocol IDs:
CHNT-RAPID
, RAPID, ISRCTN99811594, EU-20931, NCT00943423
17.
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
FM-HD09-01
, EudraCT N 2009-009431-30, NCT00992030
18.
Phase II Study of Stanford V-C Chemotherapy Comprising Cyclophosphamide, Doxorubicin, Vinblastine, Prednisone, Vincristine, Bleomycin, and Etoposide With Low-Dose Radiotherapy in Patients With Stage I or IIA Hodgkin's Lymphoma With a Favorable Prognosis
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
SUMC-G5
, NCI-V01-1671, NCT00026208
19.
Phase II Study of Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Older Patients With Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 60
Sponsor:
Other
Protocol IDs:
UON-SHIELD
, EU-20346, NCT00079105
20.
Phase II Randomized Study of Intensive Induction Chemotherapy Comprising Cisplatin, Vincristine, Bleomycin, and Carboplatin Followed By Bleomycin, Etoposide Phosphate, and Cisplatin (BEP) Versus Standard BEP Chemotherapy in Male Patients With Poor-Prognosis Extracranial Nonseminoma Germ Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
Other
Protocol IDs:
MRC-TE23
, EU-205107, ISRCTN53643604, EUDRACT-2004-000405-22, NCT00301782
21.
Therapy for Pediatric Hodgkin Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
HOD99
, NCT00145600
22.
Phase II Study of Rituximab, Doxorubicin Hydrochloride, Bleomycin, Vinblastine, and Dacarbazine in Patients With Newly Diagnosed Stage II-IV Hodgkin's Lymphoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0615
, J0615, JHOC-NA_00002473, NCT00369681
23.
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Phase:
Phase II
Type:
Natural history/Epidemiology, Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
HOD05
, NCT00352027
24.
Phase II Pilot Study of Bleomycin, Etoposide, Cisplatin, and Pegfilgrastim in Men With Metastatic Germ Cell Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 40
Sponsor:
Other
Protocol IDs:
CRCA-CCTC-ACCELERATED-BEP
, CCTC-ACCELERATED-BEP, EUDRACT-2004-000847-79, EU-20713, NCT00453232
25.
A Study of Two Associations of Rituximab and Chemotherapy, With a PET–Driven Strategy, in Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 59
Sponsor:
Other
Protocol IDs:
2007.462
, NCT00498043
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
